MSMartin Schindl

Martin Schindl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Schindl has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of video-assisted preoperative patient information on patient-reported outcomes after pancreatic resection (INFORM trial): a study protocol for a randomised controlled pilot trial

    by Charlotte Gustorff, Laura Turtschan, Jakob Mühlbacher, Carl-Stephan Leonhardt, Klaus Sahora, Martin Schindl, Oliver Strobel, Ulla Klaiber

    Introduction Undergoing pancreatic surgery represents an exceptional situation for the individual patient who therefore requires appropriate preoperative information. In daily clinical practice, however, there is often a lack of time for adequate patient information and education, which may be associated with stress, fears and worries with potentially negative impact on patient-reported and postoperative outcomes. The aim of the INFORM trial is to evaluate the impact of video-assisted preoperative patient information on patient-reported and surgical outcomes in patients scheduled for elective pancreatic resection. Methods and analysis The INFORM trial is an open-label, randomised controlled pilot trial with two parallel study groups and a planned sample size of 80 patients with any indication for pancreatic resection. The intervention group will receive access to videos providing detailed information on the planned surgery and the perioperative procedures within 2 weeks before surgery in addition to the standard preoperative preparations. The control group will only receive the standard preoperative preparations without video. Quality of life (QLQ), satisfaction with information on disease and treatment as well as disease symptoms will be assessed using the European Organisation For Research and Treatment of Cancer QLQ INFO25, C30 and PAN26 questionnaires. Surgical complications will be assessed according to appropriate classifications by Clavien and Dindo and the International Study Group of Pancreatic Surgery (ISGPS). To account for the potential impact of cancer treatment on the outcome parameters, a subgroup analysis including only patients without malignancy will be performed. In addition, potential influencing factors on QLQ scores will be investigated by comparing QLQ scores among appropriate subsets of patients. Ethics and dissemination This trial was approved by the institution’s Ethics Committee (reference number 1479/2024). All trial procedures are performed in accordance with the ICH E6 harmonised tripartite guideline on Good Clinical Practice and the ethical principles of the Declaration of Helsinki. Once the study has been completed, the results will be published in due course. Trial registration details German Clinical Trial Register number: DRKS00035173. Registered 14 October 2024 (https://drks.de/search/de/trial/DRKS00035173/details).

  • Open Access

    Obsidian ASG autologous platelet-rich fibrin matrix for the prevention of postoperative pancreatic fistula following pancreatic resection: study protocol for a feasibility trial at the Medical University of Vienna

    by Charlotte Gustorff, Christopher Dawoud, Carl-Stephan Leonhardt, Stefan Riss, Klaus Sahora, Martin Schindl, Oliver Strobel, Ulla Klaiber

    Introduction Postoperative pancreatic fistula (POPF) is the most frequent complication after partial pancreatectomy, which is by definition associated with clinical consequences requiring changes in postoperative management. Despite numerous scientific efforts, effective procedures to prevent POPF are lacking. Obsidian ASG autologous platelet-rich fibrin matrix has been effectively applied to prevent anastomotic leakage following colorectal surgery. This study is the first to investigate the feasibility of using the sealant in pancreatic surgery. Methods and analysis 25 consecutive patients scheduled for elective formal partial pancreatectomy due to any underlying disease fulfilling the eligibility criteria will be included. Obsidian ASG sealant prepared out of 120 mL of each patient’s whole blood will be applied to the pancreatic stump or the pancreatic anastomosis, respectively. The primary endpoint is the feasibility of the procedure, for example, the proportion of patients undergoing successful trial intervention. Secondary endpoints comprise safety and surgical outcome parameters including rate and severity of POPF as well as further pancreas-specific complications as defined by the International Study Group of Pancreatic Surgery during 90 days after surgery. Patients will be matched with a historic collective in a 1:2 ratio to gain first data on efficacy. Ethics and dissemination This trial and the associated study protocol (V.1.1.1, date 26 March 2024) were approved by the institution’s ethics committee (reference number 2191/2023). All trial procedures are performed in accordance with the International Council for Harmonisation harmonised tripartite guideline on Good Clinical Practice and the ethical principles of the Declaration of Helsinki. After completion of the study, results will be published in due course. Trial registration number The trial was registered in the German Clinical Trials Register on 6 May 2024 (DRKS-ID: DRKS00034052).


  • Open Access

    A systematic review and meta-analysis of morbidity and pancreatic fistula after distal pancreatectomy with versus without prophylactic intra-abdominal drainage

    by Ulla Klaiber, Philip M. Collins, Simon Trinkler, Charlotte Gustorff, Martin Schindl, Klaus Sahora, Carl-Stephan Leonhardt, Oliver Strobel

    Background: The omission of a prophylactic intra-abdominal drainage has been under debate in pancreatic surgery due to the high-risk of complications and especially of postoperative pancreatic fistula (POPF). Recently, the second randomized controlled trial (RCT) and two propensity score-matched comparative studies assessing risks and benefits of a no-drainage policy versus prophylactic drainage after distal pancreatectomy (DP) have been published. This systematic review with meta-analysis provides an updated summary of the available evidence on this topic. Methods: RCTs and nonrandomized comparative studies (NCS) investigating outcomes of no drainage versus drainage after DP were searched systematically in MEDLINE, Embase, and CENTRAL. Random effects meta-analyses were performed, and the results presented as weighted odds ratios (OR) or mean differences with their corresponding 95% CI. Subgroup analyses were performed to account for interstudy heterogeneity between RCTs and NCS. Results: Two RCTs and six NCS with a total of 3610 patients undergoing DP were included of whom 1038 (28.8%) patients did not receive prophylactic drainage. A no-drainage policy was associated with significantly lower risks of POPF (OR 0.38, 95% CI: 0.25–0.56; PP=0.008), less reinterventions (OR 0.70, 95% CI: 0.52–0.95; P=0.02), and fewer readmissions (OR 0.69, 95% CI: 0.54–0.88; P=0.003) as well as shorter length of hospital stay (mean differences −1.74, 95% CI: −2.70 to −0.78; P=0.0004). Subgroup analyses including only RCTs confirmed benefits of the no-drainage policy. Conclusion: A no-drainage policy is associated with reduced POPF and morbidity and can therefore be recommended as standard procedure in patients undergoing DP.


  • Open Access

    Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis

    by Carl-Stephan Leonhardt, Thomas Hank, Dietmar Pils, Charlotte Gustorff, Klaus Sahora, Martin Schindl, Caroline S. Verbeke, Oliver Strobel, Ulla Klaiber

    Background: A greater than 1 mm tumour-free resection margin (R0 >1 mm) is a prognostic factor in upfront-resected pancreatic ductal adenocarcinoma. After neoadjuvant treatment (NAT); however, the prognostic impact of resection margin (R) status remains controversial. Methods: Randomised and non-randomised studies assessing the association of R status and survival in resected pancreatic ductal adenocarcinoma after NAT were sought by systematic searches of MEDLINE, Web of Science and CENTRAL. Hazard ratios (HR) and their corresponding 95% CI were collected to generate log HR using the inverse-variance method. Random-effects meta-analyses were performed and the results presented as weighted HR. Sensitivity and meta-regression analyses were conducted to account for different surgical procedures and varying length of follow-up, respectively. Results: Twenty-two studies with a total of 4929 patients were included. Based on univariable data, R0 greater than 1 mm was significantly associated with prolonged overall survival (OS) (HR 1.76, 95% CI 1.57–1.97; PPPP=0.0003). Results for R1 direct were comparable in the entire cohort; however, no prognostic impact was detected in sensitivity analysis including only partial pancreatoduodenectomies. Conclusion: After NAT, a tumour-free margin greater than 1 mm is independently associated with improved OS as well as DFS in patients undergoing surgical resection for pancreatic cancer.


  • Open Access

    Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment

    by Gerd Jomrich, Maximilian Gruber, Elisabeth S. Gruber, Jakob Mühlbacher, Sanja Radosavljevic, Lavinia Wilfing, Daniel Winkler, Gerald Prager, Christian Reiterer, Barbara Kabon, et al.


  • Open Access

    The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment

    by Carl-Stephan Leonhardt, Dietmar Pils, Motaz Qadan, Gerd Jomrich, Charnwit Assawasirisin, Ulla Klaiber, Klaus Sahora, Andrew L. Warshaw, Cristina R. Ferrone, Martin Schindl, et al.

    Objective: To investigate the oncological outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) who had an R0 or R1 resection based on the revised R status (1 mm) after neoadjuvant therapy (NAT). Background: The revised R status is an independent prognostic factor in upfront-resected PDAC; however, the significance of 1 mm margin clearance after NAT remains controversial. Methods: Patients undergoing pancreatectomy after NAT for PDAC were identified from 2 prospectively maintained databases. Clinicopathological and survival data were analyzed. The primary outcomes were overall survival (OS), recurrence-free survival (RFS), and pattern of recurrence in association with R0 >1 mm and R1 ≤1 mm resections. Results: Three hundred fifty-seven patients with PDAC were included after NAT and subsequent pancreatic resection. Two hundred eight patients (58.3%) received FOLFIRINOX, 41 patients (11.5%) received gemcitabine-based regimens, and 299 individuals (83.8%) received additional radiotherapy. R0 resections were achieved in 272 patients (76.2%) and 85 patients (23.8%) had R1 resections. Median OS after R0 was 41.0 months, compared with 20.6 months after R1 resection (P = 0.002), and even longer after additional adjuvant chemotherapy (R0 44.8 vs R1 20.1 months; P = 0.0032). Median RFS in the R0 subgroup was 17.5 months versus 9.4 months in the R1 subgroup (P < 0.0001). R status was confirmed as an independent predictor for OS (R1 hazard ratio: 1.56, 95% CI: 1.07–2.26) and RFS (R1 hazard ratio: 1.52; 95% CI: 1.14–2.0). In addition, R1 resections were significantly associated with local but not distant recurrence (P < 0.0005). Conclusions: The revised R status is an independent predictor of postresection survival and local recurrence in PDAC after NAT. Achieving R0 resection with a margin of at least 1 mm should be a primary goal in the surgical treatment of PDAC after NAT.


  • The faith of non-surveilled pancreatic cysts: a bicentric retrospective study

    by N. Surci, G. Marchegiani, S. Andrianello, T. Pollini, J. Mühlbacher, G. Jomrich, P. Richwien, D. Tamandl, M. Schindl, C. Bassi, et al.


  • Open Access

    Pankreasfisteln nach Pankreasresektion – was nun?

    by Martin Schindl

    Zusammenfassung: Das Auftreten einer Fistel nach einer Pankreasoperation kann von hoher klinischer Relevanz für den postoperativen Verlauf sein. Die Berücksichtigung von Risikofaktoren erlaubt die Anwendung von Strategien zur Vorbeugung klinisch relevanter postoperativer Pankreasfisteln durch „Abschwächung“ ihres natürlichen Verlaufs. Durch die regelmäßige Kontrolle von klinischen Befunden, Blutlabor und Drainageflüssigkeit in der postoperativen Phase nach Pankreasoperation können Komplikationen, die in Zusammenhang mit Pankreasfisteln auftreten, rechtzeitig erkannt und erfolgreich behandelt werden. Ein „Step-up-Approach“ hat sich insbesondere bei der Behandlung von Abszessen und Blutungen bewährt.

  • Open Access

    Imaging of inflammatory disease of the pancreas

    by Nina Bastati, Antonia Kristic, Sarah Poetter-Lang, Alina Messner, Alexander Herold, Jacqueline C Hodge, Martin Schindl, Ahmed Ba-Ssalamah

    Increasingly acute and chronic pancreatitis (AP and CP) are considered a continuum of a single entity. Nonetheless, if, after flare-up, the pancreas shows no residual inflammation, it is classified as AP. CP is characterised by a long cycle of worsening and waning glandular inflammation without the pancreas ever returning to its baseline structure or function. According to the International Consensus Guidelines on Early Chronic Pancreatitis, pancreatic inflammation must last at least 6 months before it can be labelled CP. The distinction is important because, unlike AP, CP can destroy endocrine and exocrine pancreatic function, emphasising the importance of early diagnosis. As typical AP can be diagnosed by clinical symptoms plus laboratory tests, imaging is usually reserved for those with recurrent, complicated or CP. Imaging typically starts with ultrasound and more frequently with contrast-enhanced computed tomography (CECT). MRI and/or MR cholangiopancreatography can be used as a problem-solving tool to confirm indirect signs of pancreatic mass, differentiate between solid and cystic lesions, and to exclude pancreatic duct anomalies, as may occur with recurrent AP, or to visualise early signs of CP. MR cholangiopancreatography has replaced diagnostic endoscopic retrograde cholangiopancreatography (ERCP). However, ERCP, and/or endoscopic ultrasound (EUS) remain necessary for transpapillary biliary or pancreatic duct stenting and transgastric cystic fluid drainage or pancreatic tissue sampling, respectively. Finally, positron emission tomography-MRI or positron emission tomography-CT are usually reserved for complicated cases and/or to search for extra pancreatic systemic manifestations. In this article, we discuss a broad spectrum of inflammatory pancreatic disorders and the utility of various modalities in diagnosing acute and chronic pancreatitis.